Back to Search
Start Over
CD30 in systemic mastocytosis.
- Source :
-
Immunology and allergy clinics of North America [Immunol Allergy Clin North Am] 2014 May; Vol. 34 (2), pp. 341-55. Date of Electronic Publication: 2014 Mar 13. - Publication Year :
- 2014
-
Abstract
- CD30 is a transmembrane receptor, normally not expressed by mast cells, which regulates proliferation/apoptosis and antibody responses. Aberrant expression of CD30 by mastocytosis mast cells and interaction with its ligand CD30L (CD153) appears to play an important role in the pathogenesis and clinical presentation of systemic mastocytosis. This article highlights the expression profile and role of CD30 and CD30L in physiologic and pathologic conditions, the applicability of CD30 as a marker for systemic mastocytosis, the consequences of mast cell-expressed CD30, and the possibility of future anti-CD30 based cytoreductive therapies.<br /> (Crown Copyright © 2014. Published by Elsevier Inc. All rights reserved.)
- Subjects :
- Adult
Antibodies therapeutic use
B-Lymphocytes immunology
CD30 Ligand blood
CD30 Ligand genetics
CD30 Ligand immunology
Humans
Ki-1 Antigen antagonists & inhibitors
Ki-1 Antigen blood
Ki-1 Antigen immunology
Lymphocyte Activation
Mast Cells immunology
Mastocytosis, Systemic drug therapy
Mastocytosis, Systemic genetics
Mastocytosis, Systemic pathology
Prognosis
Signal Transduction
T-Lymphocytes immunology
B-Lymphocytes pathology
Gene Expression Regulation, Neoplastic
Ki-1 Antigen genetics
Mast Cells pathology
Mastocytosis, Systemic diagnosis
T-Lymphocytes pathology
Subjects
Details
- Language :
- English
- ISSN :
- 1557-8607
- Volume :
- 34
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Immunology and allergy clinics of North America
- Publication Type :
- Academic Journal
- Accession number :
- 24745678
- Full Text :
- https://doi.org/10.1016/j.iac.2014.01.006